Juno Therapeutics Inc (JUNO) CEO Sells $12,477,442.50 in Stock

Juno Therapeutics Inc (NASDAQ:JUNO) CEO Hans Edgar Bishop sold 270,250 shares of the company’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the completion of the sale, the chief executive officer now owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Juno Therapeutics Inc (NASDAQ:JUNO) traded up $0.15 during midday trading on Monday, reaching $85.84. The company’s stock had a trading volume of 2,971,635 shares, compared to its average volume of 6,280,425. The stock has a market cap of $9,810.00, a P/E ratio of -25.32 and a beta of 3.42. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics Inc has a 12 month low of $19.62 and a 12 month high of $86.28.

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. restated a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Raymond James Financial restated a “buy” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Wells Fargo & Co reaffirmed a “market perform” rating and issued a $63.00 price target (up previously from $54.00) on shares of Juno Therapeutics in a report on Wednesday, January 17th. Barclays cut Juno Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $55.00 to $87.00 in a report on Wednesday, January 24th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $56.00 price target on shares of Juno Therapeutics in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the company’s stock. Juno Therapeutics has a consensus rating of “Hold” and an average target price of $51.20.

A number of hedge funds and other institutional investors have recently made changes to their positions in JUNO. The Manufacturers Life Insurance Company lifted its holdings in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 228 shares during the last quarter. Advisor Group Inc. increased its position in shares of Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares in the last quarter. QS Investors LLC acquired a new position in Juno Therapeutics in the 2nd quarter valued at about $135,000. Bronfman E.L. Rothschild L.P. increased its position in Juno Therapeutics by 27,376.9% in the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 3,559 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in Juno Therapeutics in the 4th quarter valued at about $173,000. 68.90% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Juno Therapeutics Inc (JUNO) CEO Sells $12,477,442.50 in Stock” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.thelincolnianonline.com/2018/02/12/juno-therapeutics-inc-juno-ceo-sells-12477442-50-in-stock-updated-updated-updated.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply